IL159296A0 - Lactone formulations and method of use - Google Patents

Lactone formulations and method of use

Info

Publication number
IL159296A0
IL159296A0 IL15929602A IL15929602A IL159296A0 IL 159296 A0 IL159296 A0 IL 159296A0 IL 15929602 A IL15929602 A IL 15929602A IL 15929602 A IL15929602 A IL 15929602A IL 159296 A0 IL159296 A0 IL 159296A0
Authority
IL
Israel
Prior art keywords
lactone
formulations
lactone formulations
Prior art date
Application number
IL15929602A
Other languages
English (en)
Original Assignee
Magnachem Int Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magnachem Int Lab Inc filed Critical Magnachem Int Lab Inc
Publication of IL159296A0 publication Critical patent/IL159296A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL15929602A 2001-06-13 2002-06-12 Lactone formulations and method of use IL159296A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29787501P 2001-06-13 2001-06-13
PCT/US2002/018602 WO2002100854A1 (fr) 2001-06-13 2002-06-12 Formulation de lactone et procede d'utilisation

Publications (1)

Publication Number Publication Date
IL159296A0 true IL159296A0 (en) 2004-06-01

Family

ID=23148076

Family Applications (3)

Application Number Title Priority Date Filing Date
IL15929602A IL159296A0 (en) 2001-06-13 2002-06-12 Lactone formulations and method of use
IL159296A IL159296A (en) 2001-06-13 2003-12-10 Lacton preparations
IL211958A IL211958A0 (en) 2001-06-13 2011-03-27 Lactone formulations and method of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL159296A IL159296A (en) 2001-06-13 2003-12-10 Lacton preparations
IL211958A IL211958A0 (en) 2001-06-13 2011-03-27 Lactone formulations and method of use

Country Status (21)

Country Link
US (3) US6900242B2 (fr)
EP (1) EP1406895B1 (fr)
JP (1) JP2005500289A (fr)
KR (1) KR20040030676A (fr)
AR (1) AR036056A1 (fr)
AT (1) ATE406367T1 (fr)
AU (1) AU2002306150B2 (fr)
BR (1) BR0210432A (fr)
CA (1) CA2450660C (fr)
CO (1) CO5550429A2 (fr)
CY (1) CY1108590T1 (fr)
DE (1) DE60228576D1 (fr)
DK (1) DK1406895T3 (fr)
ES (1) ES2315365T3 (fr)
IL (3) IL159296A0 (fr)
MX (1) MXPA03011554A (fr)
PT (1) PT1406895E (fr)
RS (1) RS52139B (fr)
UY (1) UY27334A1 (fr)
WO (1) WO2002100854A1 (fr)
ZA (1) ZA200400208B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450660C (fr) * 2001-06-13 2011-08-16 Magnachem International Laboratories, Inc. Formulation de lactone et procede d'utilisation
US8188145B2 (en) 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US7323495B2 (en) * 2002-11-05 2008-01-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US20050045197A1 (en) * 2003-08-28 2005-03-03 Gelder Steven K. Multiple drug delivery system & method
CN102265154A (zh) * 2008-10-24 2011-11-30 马格纳化学国际实验室公司 用于筛选与rad9选择性相互作用的化合物的方法
CN103099901B (zh) * 2013-01-26 2014-07-30 张红 一种治疗子宫内膜移位症的中药灌肠剂
KR101988479B1 (ko) * 2017-10-11 2019-09-24 (주)휴럼 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2624723A (en) * 1947-03-03 1953-01-06 Allied Chem & Dye Corp Lactone derivatives and method of making
US2624732A (en) * 1950-05-10 1953-01-06 Burroughs Wellcome Co Preparation of 5-benzyl-2,4-diaminopyrimidines
US3203953A (en) * 1963-01-18 1965-08-31 Ciba Geigy Corp Lactone obtained from helenium sp. and derivatives thereof
US3210377A (en) * 1963-06-05 1965-10-05 Olin Mathieson Gamma lactones
US4001425A (en) * 1974-04-17 1977-01-04 E. I. Du Pont De Nemours And Company Methods of treating hypertension and pharmaceutical compositions comprising 1-tertiary-alkyl-3-(substituted furyl)ureas as antihypertensive agents
JPS5111173B2 (fr) * 1974-04-25 1976-04-09
JPS51125722A (en) 1975-01-13 1976-11-02 Sumitomo Chem Co Ltd Germicides for industry and their preparation
JPS597713B2 (ja) 1977-12-19 1984-02-20 三井東圧化学株式会社 新規γ↓−ブチロラクトン誘導体とその製造法
JPS56128776A (en) 1980-03-14 1981-10-08 Otsuka Pharmaceut Factory Inc Alpha-methylene gamma-butyrolactone derivative
JPS58199413A (ja) 1982-05-13 1983-11-19 Pioneer Electronic Corp デイジタル変調信号の読取装置
JPS6058973A (ja) * 1983-09-13 1985-04-05 Mitsubishi Yuka Yakuhin Kk γ−プチロラクトン誘導体及びそれを有効成分とする免疫調節剤
JPS6226221A (ja) 1985-07-29 1987-02-04 Japan Tobacco Inc 抗変異原性剤
JP2524760B2 (ja) 1987-07-10 1996-08-14 テイカ株式会社 新規抗生物質
JPH01163175A (ja) 1987-12-21 1989-06-27 Ss Pharmaceut Co Ltd フラン−２−オン誘導体
US5242945A (en) * 1991-04-12 1993-09-07 American Home Products Corporation Tetronic and thiotetronic acid derivatives as phospholipase a2 inhibitors
US5250735A (en) * 1992-04-03 1993-10-05 University Of Pittsburgh 2-(N-substituted-aminoalkyl)-5-(E)-alkylidene cyclopentanones, 2-(N-substituted-aminoalkyl)-5-(E)-arylalkylidene cyclopentanones, and derivatives thereof
JPH09502713A (ja) * 1993-09-17 1997-03-18 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0854138B1 (fr) 1994-06-07 2001-05-23 Teijin Limited Dérivé de Vitamine D3 et un procédé de production dudit dérivé
AUPN191295A0 (en) 1995-03-23 1995-04-27 Unisearch Limited Microbiocide or microbial regulator
US5962460A (en) * 1995-06-27 1999-10-05 National Science Council (Taiwan) Antineoplastic α-methylene-γ-butyrolactones
US5646164A (en) * 1995-11-14 1997-07-08 National Science Council α-methylene-γ-butyrolactones: new inhibitors of platelet aggregation
ATE303144T1 (de) 1995-11-17 2005-09-15 Univ Johns Hopkins Hemmung der fettsäuresynthase als mittel zur verminderung der adipozytenmenge
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
EP0971910A1 (fr) 1997-04-02 2000-01-19 Merck Frosst Canada & Co. Lactones gamma alpha-methylene utilisees comme inhibiteurs selectifs de la cyclooxygenase-2
US5905089A (en) * 1997-04-14 1999-05-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Use of sesquiterpene lactones for treatment of severe inflammatory disorders
AUPP303498A0 (en) 1998-04-17 1998-05-14 Unisearch Limited Inhibition of gram positive bacteria
JP2002517423A (ja) * 1998-06-08 2002-06-18 アドバンスド メディスン インコーポレーテッド シクロオキシゲナーゼ−２の多結合インヒビター
WO2000058297A2 (fr) * 1999-03-30 2000-10-05 E.I. Du Pont De Nemours And Company PROCEDE DE PREPARATION D'α-METHYLENELACTONES
FR2801792B1 (fr) 1999-12-01 2003-04-18 Sod Conseils Rech Applic Un nouveau medicament, le dihydromikanolide, son obtention par extraction de la plante mikania micrantha et son utilisation comme agent anti-proliferatif
US6660511B1 (en) 2000-03-03 2003-12-09 Rigel Pharmaceuticals, Inc. Methods of screening for modulation of cell cycle
AU2001258677A1 (en) * 2000-05-22 2001-12-03 Dr. Reddy's Research Foundation Novel compounds having antiinflammatory activity: process for their preparation and pharmaceutical compositions containing them
JP2002037797A (ja) 2000-07-25 2002-02-06 Kanegafuchi Chem Ind Co Ltd マクロファージ選択的細胞死誘導物質
US7084117B2 (en) 2001-01-12 2006-08-01 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof
CA2450660C (fr) * 2001-06-13 2011-08-16 Magnachem International Laboratories, Inc. Formulation de lactone et procede d'utilisation
US6686724B2 (en) * 2002-05-21 2004-02-03 Ford Motor Company Method of and apparatus for controlling charging and/or discharging of a battery for a hybrid electric vehicle
US8188145B2 (en) * 2002-06-12 2012-05-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use
US7323495B2 (en) * 2002-11-05 2008-01-29 Magnachem International Laboratories, Inc. Synthetic lactone formulations and method of use

Also Published As

Publication number Publication date
UY27334A1 (es) 2003-02-28
CO5550429A2 (es) 2005-08-31
KR20040030676A (ko) 2004-04-09
CA2450660C (fr) 2011-08-16
ATE406367T1 (de) 2008-09-15
EP1406895A4 (fr) 2004-11-17
IL211958A0 (en) 2011-06-30
ZA200400208B (en) 2005-06-29
US6900242B2 (en) 2005-05-31
US20050209316A1 (en) 2005-09-22
RS98603A (en) 2006-12-15
AR036056A1 (es) 2004-08-04
AU2002306150B2 (en) 2008-02-14
RS52139B (en) 2012-08-31
JP2005500289A (ja) 2005-01-06
CA2450660A1 (fr) 2002-12-19
MXPA03011554A (es) 2004-10-28
CY1108590T1 (el) 2014-04-09
WO2002100854A1 (fr) 2002-12-19
EP1406895A1 (fr) 2004-04-14
ES2315365T3 (es) 2009-04-01
US20030069393A1 (en) 2003-04-10
DK1406895T3 (da) 2008-12-01
DE60228576D1 (de) 2008-10-09
PT1406895E (pt) 2008-11-04
BR0210432A (pt) 2004-08-03
US8536348B2 (en) 2013-09-17
EP1406895B1 (fr) 2008-08-27
IL159296A (en) 2011-06-30
US20110092588A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
EP1420825A4 (fr) Composes immunomodulants et methodes d'utilisation
HUP0303732A2 (en) Hsa-free formulations of interferon-beta
AU2002230831A1 (en) Compositions of human proteins and method of use thereof
PL348343A1 (en) Method of obtaining prolonged-release microparticles and prolonged-release microparticles as such
AU2002314466A1 (en) Withasol and methods of use
IL211958A0 (en) Lactone formulations and method of use
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2002335085A1 (en) Angiopoietins and methods of use thereof
IL160835A0 (en) Catheter and method of using same
ZA200306573B (en) A vaccine composition and method of using the same
HU0104832D0 (en) Cosmetic composition and method
EP1263935A4 (fr) Scytonemine et ses procedes d'utilisation
IL160794A0 (en) An enantiomerically pure diarylmethylpiperazine and methods of using same
AU2003287546A8 (en) Synthetic lactone formulations and method of use
GB0105472D0 (en) Smoke composition and method of use thereof
EP1414427A4 (fr) Compositions a base de kavalactone et leurs procedes d'utilisation
GB2394359B (en) Microelctronic device and method of its manufacture
AUPQ760400A0 (en) Herbical formulations and methods of use thereof
EP1392460A4 (fr) Hydrofluorures d'aminosilanols et leur utilisation
PL351128A1 (en) Method of obtaining phenoglycine and derivatives thereof
AU2002235438A1 (en) Exercise device and method of use
EP1362193A4 (fr) Cheville et procede d'utilisation
EP1435953A4 (fr) Composes antivesicants et procedes de fabrication et d'utilisation associes
WO2003016502A9 (fr) Tramdorines et procede d'utilisation de tramdorines
AU1484302A (en) Improved endosulfan formulation and methods of use thereof